Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02500576
Title MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.